Improving Noninvasive Methods of Assessing Liver Fibrosis in Patients With Hepatitis C Virus/Human Immunodeficiency Virus Co-infection

被引:14
|
作者
Shire, Norah J. [1 ,2 ]
Rao, Marepalli B. [2 ]
Succop, Paul [2 ]
Buncher, C. Ralph [2 ]
Andersen, Janet A. [3 ]
Butt, Adeel A. [4 ]
Chung, Raymond T. [5 ]
Sherman, Kenneth E. [6 ]
机构
[1] Merck & Co Inc, Infect Dis Epidemiol, N Wales, PA 19545 USA
[2] Univ Cincinnati, Coll Med, Div Epidemiol & Biostat, Cincinnati, OH USA
[3] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA
[4] Univ Pittsburgh, Sch Med, Div Digest Dis, Pittsburgh, PA USA
[5] Massachusetts Gen Hosp, Dept Gastroenterol & Hepatol, Boston, MA 02114 USA
[6] Univ Cincinnati, Coll Med, Div Digest Dis, Cincinnati, OH USA
关键词
INFECTED PATIENTS; MARKERS; CIRRHOSIS; INDEX; PREDICTION; VALIDATION; FIBROTEST; RATIO; SCORE; HIV;
D O I
10.1016/j.cgh.2008.12.016
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Liver fibrosis is a significant concern for patients with hepatitis C virus/human immunodeficiency virus co-infection. Fibrosis staging by biopsy is accurate, but costly and invasive. Several fibrosis prediction models using noninvasive biomarkers have been developed but are suboptimal in co-infected patients. We compared results from different staging models and ordinal regression with biopsy data. Methods: Data from the Adult Acquired Immune Deficiency Syndrome Clinical Trials Group protocol A5178 were used to evaluate 5 models of fibrosis staging; areas under receiver-operator characteristic curves (AUROC) were assessed. Individual covariates were assessed with univariable regression and then entered into an ordinal logistic regression model from which a stage-wise index was developed. Results: Data from 173 patients were evaluated; 85% were on antiretroviral therapy, 31.2% had severe fibrosis (F3/F4), and 14% had cirrhosis (F4). Differences in CD4+ cell and platelets counts and international normalized ratio values were observed between those with and without F3/F4. Among existing models, the FIB-4 index ([age X AST])/[platelet count x (ALT)(1/2)]) performed best, with 88% specificity for F4 and greater than 86% negative predictive values for F3/F4, although AUROC values were low (0.56 +/- 0.03 for F3/F4). By using patients' demographic, clinical, and laboratory data, the ordinal regression model outperformed others, with an AUROC of 0.85 (standard error, 0.03) for predicting stage F3/F4 and 0.89 (standard error, 0.05) for stage 3 alone. Conclusion : Current noninvasive methods of fibrosis assessment have poor discriminatory capacity in hepatitis C virus/human immunodeficiency virus co-infected patients. Ordinal regression analysis outperformed other noninvasive fibrosis prediction models. Longitudinal studies with paired biopsies will assist in refining the Ordinal Regression Index.
引用
收藏
页码:471 / 480
页数:10
相关论文
共 50 条
  • [1] Hepatitis C virus and human immunodeficiency virus co-infection
    Pol, S
    [J]. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2001, 25 (04): : B152 - B156
  • [2] Liver transplantation for patients with human immunodeficiency virus and hepatitis C virus co-infection: update in 2013
    Eguchi, Susumu
    Takatsuki, Mitsuhisa
    Kuroki, Tamotsu
    [J]. JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2014, 21 (04) : 263 - 268
  • [3] Human immunodeficiency virus and hepatitis C virus co-infection in Burundi
    Ntagirabiri, R.
    Ngendakumana, F.
    Niyongabo, T.
    [J]. JOURNAL AFRICAIN D HEPATO-GASTROENTEROLOGIE, 2012, 6 (02): : 128 - 131
  • [4] An update on the management of hepatitis C virus and human immunodeficiency virus co-infection
    Tolentino, Bryan
    Singh, Ritu R.
    Misra, Suresh
    Dieterich, Douglas T.
    Sarpel, Dost
    [J]. FUTURE VIROLOGY, 2019, 14 (03) : 185 - 195
  • [5] Diagnostic accuracy of the Coopscore© to predict liver fibrosis in human immunodeficiency virus/hepatitis B virus co-infection
    Taibi, Ludmia
    Boyd, Anders
    Bosselut, Nelly
    Bottero, Julie
    Guechot, Jerome
    Lacombe, Karine
    Lasnier, Elisabeth
    Baudin, Bruno
    Vaubourdolle, Michel
    [J]. ANNALS OF CLINICAL BIOCHEMISTRY, 2018, 55 (02) : 236 - 243
  • [6] Enhancing current human immunodeficiency virus/hepatitis B and human immunodeficiency virus/hepatitis C virus co-infection management
    Huang Zhan-Lian
    Chen Da-Biao
    Gao Zhi-Liang
    Lin Bing-Liang
    [J]. 中华医学杂志(英文版), 2020, 133 (23) : 2890 - 2891
  • [7] Enhancing current human immunodeficiency virus/hepatitis B and human immunodeficiency virus/hepatitis C virus co-infection management
    Huang, Zhan-Lian
    Chen, Da-Biao
    Gao, Zhi-Liang
    Lin, Bing-Liang
    [J]. CHINESE MEDICAL JOURNAL, 2020, 133 (23) : 2890 - 2891
  • [8] Hepatitis C virus treatment and survival in patients with hepatitis C and human immunodeficiency virus co-infection and baseline anaemia
    Erqou, S.
    Mohanty, A.
    McGinnis, K. A.
    Vanasse, G.
    Freiberg, M. S.
    Sherman, K. E.
    Butt, A. A.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2013, 20 (07) : 463 - 469
  • [9] Hepatitis B and Hepatitis C Virus Co-infection among Human Immunodeficiency Virus Infected Patients of Tripura
    Bhaumik, Pradip
    Bhattacharjee, Prasun
    Sil, Samir Kumar
    [J]. INTERNATIONAL JOURNAL OF SCIENTIFIC STUDY, 2015, 3 (06) : 77 - 80
  • [10] Non-initiation of hepatitis C virus antiviral therapy in patients with human immunodeficiency virus/hepatitis C virus co-infection
    Christine U Oramasionwu
    Angela DM Kashuba
    Sonia Napravnik
    David A Wohl
    Lu Mao
    Adaora A Adimora
    [J]. World Journal of Hepatology, 2016, 8 (07) : 368 - 375